DK2726507T3 - ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE - Google Patents

ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE Download PDF

Info

Publication number
DK2726507T3
DK2726507T3 DK12729996.4T DK12729996T DK2726507T3 DK 2726507 T3 DK2726507 T3 DK 2726507T3 DK 12729996 T DK12729996 T DK 12729996T DK 2726507 T3 DK2726507 T3 DK 2726507T3
Authority
DK
Denmark
Prior art keywords
ser
gly
antibody
thr
lys
Prior art date
Application number
DK12729996.4T
Other languages
Danish (da)
English (en)
Inventor
Michael Bachmann
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Application granted granted Critical
Publication of DK2726507T3 publication Critical patent/DK2726507T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK12729996.4T 2011-06-30 2012-06-29 ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE DK2726507T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Publications (1)

Publication Number Publication Date
DK2726507T3 true DK2726507T3 (en) 2019-03-11

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12729996.4T DK2726507T3 (en) 2011-06-30 2012-06-29 ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE

Country Status (18)

Country Link
US (1) US9200078B2 (enExample)
EP (2) EP3505536B1 (enExample)
JP (4) JP2014528696A (enExample)
AU (1) AU2012277784B2 (enExample)
CY (1) CY1121249T1 (enExample)
DE (1) DE102011118022B4 (enExample)
DK (1) DK2726507T3 (enExample)
ES (2) ES2711978T3 (enExample)
HR (1) HRP20190289T1 (enExample)
HU (1) HUE042008T2 (enExample)
LT (1) LT2726507T (enExample)
PL (1) PL2726507T3 (enExample)
PT (1) PT2726507T (enExample)
RS (1) RS58448B1 (enExample)
SI (1) SI2726507T1 (enExample)
SM (1) SMT201900085T1 (enExample)
TR (1) TR201901991T4 (enExample)
WO (1) WO2013001065A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
ES2986967T3 (es) 2018-02-08 2024-11-13 Dragonfly Therapeutics Inc Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
BR112020016939A2 (pt) 2018-02-20 2020-12-15 Dragonfly Therapeutics, Inc. Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
SG11202100883SA (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
EP2343085B1 (en) * 1997-03-10 2014-12-10 The Regents of The University of California Antibody against prostate stem cell antigen (PSCA)
ES2309012T3 (es) * 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
MXPA06004035A (es) * 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
AU2005250370B2 (en) * 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
JP6126773B2 (ja) * 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
JP6886491B2 (ja) 2021-06-16
DE102011118022B4 (de) 2018-01-18
ES2989975T3 (es) 2024-11-28
JP2021121201A (ja) 2021-08-26
HRP20190289T1 (hr) 2019-05-03
AU2012277784A1 (en) 2014-02-06
CY1121249T1 (el) 2020-05-29
US9200078B2 (en) 2015-12-01
LT2726507T (lt) 2019-04-10
DE102011118022A1 (de) 2013-01-03
PT2726507T (pt) 2019-02-26
TR201901991T4 (tr) 2019-03-21
JP6549622B2 (ja) 2019-07-24
JP2017104113A (ja) 2017-06-15
US20140134155A1 (en) 2014-05-15
PL2726507T3 (pl) 2019-06-28
JP2014528696A (ja) 2014-10-30
WO2013001065A1 (de) 2013-01-03
SI2726507T1 (sl) 2019-05-31
ES2711978T3 (es) 2019-05-08
HUE042008T2 (hu) 2019-06-28
EP2726507B1 (de) 2018-11-21
JP2019193652A (ja) 2019-11-07
AU2012277784B2 (en) 2015-08-20
EP3505536A1 (de) 2019-07-03
SMT201900085T1 (it) 2019-05-10
EP3505536C0 (de) 2024-08-07
RS58448B1 (sr) 2019-04-30
JP7341185B2 (ja) 2023-09-08
EP2726507A1 (de) 2014-05-07
EP3505536B1 (de) 2024-08-07

Similar Documents

Publication Publication Date Title
DK2726507T3 (en) ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE
JP7642010B2 (ja) 改良された抗原結合受容体
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
KR101837053B1 (ko) 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체
KR101820535B1 (ko) 종간특이적 ｐｓｍａｘｃｄ3 이중특이적 단일쇄 항체
KR101940944B1 (ko) 종간 특이적 ｃｄ３―입실론 결합 도메인
KR20230024984A (ko) Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
KR20220035367A (ko) 항-dll3 키메라 항원 수용체 및 이의 용도
JP2023547447A (ja) 改良型抗原結合受容体
CN115551891A (zh) 用于治疗癌症的嵌合抗原受体及相关方法和组合物
JP2025540340A (ja) キメラ抗原受容体
KR20210143096A (ko) Cd22에 특이적인 항체 및 이의 용도
RU2825816C2 (ru) Улучшенные антигенсвязывающие рецепторы
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
KR20220143904A (ko) 사람 4-1bb 항진제 항체 및 이의 사용 방법
CN116018351A (zh) 靶向cd123的抗体、嵌合抗原受体及其用途
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof